In the interview, he talks about the advances in tissue and genome engineering in human pluripotent stem cells that have unlocked the potential to better understand diseases, while the ability to create organoids and the development of gene editing techniques are promising even more breakthroughs in the future.
In particular, he talks about his work in Nuria Montserrat’s IBEC group using CRISPR to study kidney disease with hPSCs, and his hopes that these approaches will provide the ideal platform for identifying biomarkers for early cancer detection, or to generate kidney canceroids useful for personalised medicine.
Read the article here.
